Dirk Schadendorf: h-index, Total Citations, and Citation Map
Dirk Schadendorf's h-index is 191 (1010 i10-index, 248,865+ total citations across 3+ publications) according to Google Scholar as of May 2026. Dirk Schadendorf is affiliated with Professor für Dermatologie, University Hospital Essen; University of Duisburg-Essen.
Dirk Schadendorf is a researcher affiliated with Professor für Dermatologie, University Hospital Essen; University of Duisburg-Essen, specializing in Cancer, melanoma, translational research. Their work has been cited 248,865 times. This profile visualizes their global influence, highlighting strong citation networks in China.
Dirk Schadendorf's Citation Metrics
Bibliometric impact based on 3 indexed publications.
- H-Index
- 191
- i10-Index
- 1010
- Total Citations
- 248,865
- Citing Countries
- 19
As of May 2026.
Dirk Schadendorf has an h-index of 191 and 248,865 total citations across 3 publications, with research cited by institutions in 19 countries.
Download Exports (PNG, CSV, Poster)
Free Viewing Dirk Schadendorf's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
We've mapped 5,000 of 248,865 citations for Dirk Schadendorf
We've shown the most-cited 5,000. Unlock the full crawl (248,851 more citations) to see every institution citing this scholar.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Top Cited Works
Tip: clickto hide a row from the map
Improved survival with ipilimumab in patients with metastatic melanoma
201019,106
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Significant Contributions
Auto-detected research lines — a seminal paper and the follow-up work building on it. Review and edit before using in a petition. Each Free PDF opens in a new tab — EB-1A organises this into the structure USCIS applies to Criterion 5 of 8 CFR § 204.5(h)(3)(v); EB-1B re-frames it under § 204.5(i)(3) (outstanding researcher); NIW presents it under prong 2 of Matter of Dhanasar.
4 citing papers could not be classified (no author data) — excluded from the percentages above.
The researcher published a seminal 2010 NEJM study demonstrating improved survival with ipilimumab in metastatic melanoma, a highly cited work that appears to have significantly influenced clinical oncology practice.
The researcher advanced melanoma treatment by demonstrating improved survival outcomes with vemurafenib in patients harboring the BRAF V600E mutation, establishing a critical therapeutic benchmark.
The researcher published a seminal NEJM study on combined immunotherapy for untreated melanoma, establishing a critical benchmark in oncology with over 10,000 citations.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
